Recently, CanSinoBio's Quadrivalent Conjugate Vaccine (QCV) initiated a Phase III clinical trial in Indonesia and completed the enrollment of the first subject. The clinical trial aims to evaluate the safety and immunogenicity of the vaccine in people aged 18-55 years.

Currently, rheumatic encephalitis remains a serious challenge in global public health, and vaccination is the most cost-effective and efficient way to prevent it.2022 In June, CanSinoBio's self-developed Mannhexin®, Asia's first tetravalent rheumatic encephalitis conjugate vaccine, was officially approved for marketing, which fills the gap of China's lack of high-end rheumatic encephalitis vaccines in this field. This clinical trial will expand the applicability of the quadrivalent conjugate vaccine to adults.

According to the statistics, the incidence of epidemic epidemic is found in all age groups, among which the incidence rate is higher in children under 5 years old. Usually, the incidence rate of epidemic encephalitis decreases with age, but the incidence rate of epidemic encephalitis increases in adolescents and the elderly. The adult vaccine market is expected to further expand as the public's awareness of health precautions and vaccination continues to rise.

As the world's fourth most populous country with nearly 300 million people, Indonesia is in dire need of a more effective vaccination strategy to achieve stronger herd immunity protection. At the same time, Indonesia is also the country with the largest Muslim population in the world, with about 87% of the local residents practicing Islam. CanSinoBio has a stable supply of quadrivalent influenza conjugate vaccine for use in vaccinating travelers on their annual pilgrimage and worship to Saudi Arabia.

Previously, CanSinoBio's COVID-19 vaccine, Convidecia®, was granted Halal certification by the Food, Drug and Cosmetic Evaluation Agency of the Indonesian Ulama Council, making it the world's only adenovirus-vectored COVID-19 vaccine to receive Halal certification in Indonesia. Relying on the world's leading vaccine technology platform, the company's tetravalent influenza conjugate vaccine has the potential to comply with Halal certification, which will help to rapidly promote the company's internationalization process.

In recent years, CanSinoBio has been actively cooperating with local companies in Indonesia, and in November 2022, on the occasion of the G20 Leaders' Summit, CanSinoBio and Etana, an Indonesian biopharmaceutical company, on behalf of the two countries, signed a cooperation agreement on inhalation vaccine technology and rheumatoid vaccine.

https://mp.weixin.qq.com/s?__biz=MzI0Nzc5MDU4OQ==&mid=2247494847&idx=1&sn=a1f9adebbc86054a874a65c2cb39a17d&chksm=e9a8022ddedf8b3bc66e2edbdff99950041021210643223700c4b132d6b8a4e4d25557780b3b&mpshare=1&scene=1&srcid=0326LheQTdtXNy05cGuZ4Hcd&sharer_shareinfo=defa6582938fd4b9edcbdfebe9cca7f7&sharer_shareinfo_first=defa6582938fd4b9edcbdfebe9cca7f7#rd